5 Minute Read
Resilient foundations drive UK life sciences toward broader growth in 2026
The UK life sciences sector enters 2026 from a position of resilience. While 2025 was characterised by an ever-moving policy, funding, and macro environment, the underlying fundamentals of the sector remained firmly intact.
Scientific output continued to grow, and the UK’s universities and research hospitals maintained their global influence. Despite the headlines, these foundations demonstrate the strength of the UK’s innovation ecosystem.
Venture capital investment closed 2025 at £3.37bn, representing a -12% change on the previous year. Although a moderation from the highs of 2021–2022, this level of investment still outperforms long-term historical averages and signals sustained investor confidence in the UK’s scientific base. The Government’s 2025 UK Budget further reinforced this outlook by introducing measures to support scaling, high-growth companies, and expanding capital flows into deep-tech and R&D-intensive sectors. In parallel, indications that the UK may adjust drug-pricing dynamics point to a potential reset in the relationship between government and pharma, which could improve investor appetite and commercial engagement.
As we move into 2026, the market is broadening beyond traditional wet-lab life sciences into a wider innovation economy. Adjacent fields like AI-driven drug discovery, quantum technologies, advanced materials, and synthetic biology are increasingly shaping demand.
This convergence is shifting occupier requirements toward more flexible, hybrid R&D space that blends offices, engineering zones, and lab-enabled environments.
There was a modest slowdown in take-up in 2025, though major transactions such as the Ellison Institute highlight that demand for high-quality, well-located space remains strong. We expect activity to increase in 2026, particularly in Cambridge, where several deferred requirements are likely to crystallise. Growth from adjacent sectors will further diversify demand across the Golden Triangle.
On the supply side, the Golden Triangle highlights long-term confidence, though delivery uncertainty is rising due to construction costs, financing constraints, and evolving occupier requirements. There is a pipeline of 3.3m sq ft currently under construction and a further 6.5m sq ft has planning approval, with the remainder still in early-stage proposals. Capital markets are expected to favour stabilised income over speculative development, and 2026 is likely to mark the beginning of a recapitalisation cycle, as developers reassess timelines, seek new partners, or consider asset disposals.
Figure 10: UK Life Sciences development pipeline, under construction
Trends to watch
-
Industry expansion
Life sciences activity is increasingly extending beyond traditional CL2 lab space. Growth in adjacent sectors such as AI-driven drug discovery, quantum technologies, advanced materials, and synthetic biology is driving demand for hybrid R&D environments, as neighbouring innovation ecosystems continue to scale.
-
Rent stabilisation
We expect rents to stabilise with more high-quality lab and office space coming online, reflecting a balance between supply expansion and sustained occupier demand for prime locations.
-
Demand for core locations
Increasing take-up in key clusters as occupational activity is likely to pick up, particularly in Cambridge, where major occupiers are advancing searches that were deferred over the past 12–18 months. This trend is expected to reinforce the Golden Triangle as the UK’s primary life sciences hub.
-
Recapitalisation cycle
Capital markets remain focused on stabilised, income-producing assets, with investors prioritising secure cash flows over speculative development. The peak of the capital cycle occurred in 2021, when the majority of capital was deployed, and many developers have since held assets through the market downturn. As financing conditions improve, 2026 is expected to see a recapitalisation phase, with owners extending hold periods, introducing new equity partners, or selectively bringing assets to market.
-
Development pipeline
Approximately 3.3m sq ft of life sciences space is under construction and 6.5m sq ft has planning approval, yet delivery of the wider 21m sq ft pipeline remains uncertain. Rising construction costs, financing constraints, and evolving occupier requirements are prompting developers to reassess phasing, specifications, and pre-letting thresholds to ensure viability.